Core Insights - Anixa Biosciences has received a new patent extending the protection of its CAR-T technology to 2045, enhancing its intellectual property portfolio [1][2][3] - The patent covers fundamental methods and compositions essential to Anixa's CAR-T approach, which aims to tackle challenges in treating solid tumors [2] - Anixa's CAR-T technology is currently in clinical trials for recurrent ovarian cancer at Moffitt Cancer Center, indicating progress in its therapeutic development [2][3] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a unique CAR-T technology known as chimeric endocrine receptor-T cell (CER-T) [3] - The company collaborates with leading research institutions, such as Moffitt Cancer Center and Cleveland Clinic, to develop its therapeutic and vaccine portfolios [3] - Anixa's vaccine programs target various cancers, including breast and ovarian cancer, and utilize innovative approaches to immunization [3]

Core Insights - Anixa Biosciences, Inc. is advancing its CAR-T therapy for ovarian cancer, with Dr. Robert Wenham as the principal investigator for the ongoing Phase 1 clinical trial [1][4] - Dr. Wenham will present at the 13th Annual Ovarcoming Cancer Conference, discussing advancements in ovarian cancer research and therapies, including Anixa's CAR-T therapy [2] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a therapeutic portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [4] - The company utilizes a novel CAR-T technology known as chimeric endocrine receptor-T cell (CER-T) technology, which differentiates itself by using the natural ligand of the FSHR receptor [4] - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other cancers [4] Conference Details - The Ovarcoming Cancer Conference aims to unite survivors, caregivers, and medical professionals to learn from experts in the ovarian cancer field [3] - Dr. Wenham's presentation is scheduled for September 18, 2025, from 12:05 PM to 12:30 PM CT [2]

Core Insights - Anixa Biosciences has initiated the transfer of the Investigational New Drug (IND) application for its breast cancer vaccine, which is currently held by Cleveland Clinic, to advance to a Phase 2 clinical trial [1][2][4] - The Phase 1 clinical trial has shown promising results, with over 70% of patients exhibiting immune responses, indicating the vaccine's potential effectiveness [2][4] - The breast cancer vaccine targets α-lactalbumin, a protein associated with lactation that re-emerges in many breast cancer forms, suggesting both therapeutic and preventive benefits [3][4] Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [5] - The company is developing vaccines for breast and ovarian cancer, as well as other cancers, utilizing technologies that target proteins expressed in certain cancer forms [5] - Anixa's business model involves partnerships with leading research institutions to explore and commercialize emerging technologies in cancer treatment [5]

"This newly allowed patent further illustrates the international recognition of the novelty and potential of our breast cancer vaccine," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "As we continue advancing clinical development in the U.S., this allowance further strengthens our ability to pursue strategic global opportunities in regions with a high burden of breast cancer." Breast cancer remains the most commonly diagnosed cancer in women globally and a leading cause of cancer- related de ...

Company Overview - ANIXA BIOSCIENCES INC is part of the Medical group, which consists of 984 companies and ranks 8 in the Zacks Sector Rank [2] - The company is categorized under the Medical - Biomedical and Genetics industry, which includes 492 companies and currently ranks 95 in the Zacks Industry Rank [6] Performance Metrics - ANIXA BIOSCIENCES INC has gained approximately 45.3% year-to-date, significantly outperforming the average loss of 2.9% in the Medical group [4] - The Zacks Consensus Estimate for ANIX's full-year earnings has increased by 7.3% over the past quarter, indicating improved analyst sentiment [4] - The stock currently holds a Zacks Rank of 2 (Buy), suggesting a favorable outlook for the next one to three months [3] Comparative Analysis - Another stock in the Medical sector, Mind Medicine (MindMed) Inc. (MNMD), has also shown strong performance with a year-to-date return of 39.7% and a Zacks Rank of 2 (Buy) [5] - Both ANIXA and Mind Medicine belong to the same industry, with the latter's consensus EPS estimate increasing by 4.3% over the past three months [5][6] Future Outlook - Investors interested in Medical stocks should monitor ANIXA BIOSCIENCES INC and Mind Medicine (MindMed) Inc. for potential continued strong performance [7]

Core Viewpoint - Anixa Biosciences has received a patent for its breast cancer vaccine technology, which addresses a significant unmet need in preventive oncology and has the potential for a multi-billion dollar market opportunity [1][2][5]. Company Overview - Anixa Biosciences is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes a breast cancer vaccine developed in collaboration with Cleveland Clinic [7]. - The company has a unique business model of partnering with renowned research institutions for all stages of development, allowing for continuous examination of emerging technologies [7]. Patent and Technology - The U.S. Patent Number 12,370,244 will be issued on July 29, 2025, covering methods of immunizing patients against breast cancer using human α-lactalbumin protein [1][2]. - The patent extends foundational protection for the breast cancer vaccine program into the mid-2040s, enhancing Anixa's ability to develop and commercialize immunopreventive solutions [2][6]. Market Opportunity - The breast cancer vaccine platform represents a potential multi-billion dollar market, particularly for women at elevated risk of developing triple-negative breast cancer (TNBC) [5]. - In the U.S., over 297,000 new cases of invasive breast cancer are projected in 2025, highlighting the significant need for preventive solutions [3]. Vaccine Mechanism - The investigational vaccine aims to stimulate the immune system to recognize and eliminate pre-malignant and malignant cells expressing α-lactalbumin while sparing normal tissue [4]. - By targeting this protein, which is generally absent from adult tissues except during lactation, the vaccine may minimize off-target effects and provide long-lasting immune protection [4].

Company Overview - Anixa Biosciences, Inc. (NASDAQ: ANIX) focuses on developing immunotherapies for cancer through two main platforms: a CAR-T program aimed at solid tumors and a vaccine technology that generates tumor-specific antigens [1]. Partnerships - Anixa has established partnerships with the Moffitt Cancer Center, which may enhance its research and development capabilities in the field of cancer immunotherapy [1].

Company Performance - ANIXA BIOSCIENCES INC has gained approximately 35.4% year-to-date, significantly outperforming the Medical group, which has lost about 4.1% on average [4] - The Zacks Consensus Estimate for ANIX's full-year earnings has increased by 7.3% over the past 90 days, indicating improved analyst sentiment and a more positive earnings outlook [3] Industry Context - ANIXA BIOSCIENCES INC is part of the Medical - Biomedical and Genetics industry, which includes 495 companies and currently ranks 75 in the Zacks Industry Rank. This industry has experienced an average loss of 2% year-to-date, showing that ANIX is performing better than its peers [6] - In comparison, CochLear Ltd. Unsponsored ADR, another outperforming stock in the Medical sector, has returned 9.6% since the beginning of the year and is part of the Medical Services industry, which has moved -2.4% year-to-date and ranks 64 [4][7]

Core Viewpoint - Anixa Biosciences has announced the issuance of a key patent for its ovarian cancer vaccine technology, which is expected to enhance the company's position in the cancer treatment market [1][4]. Group 1: Patent and Technology - The United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,357,593 on July 15, 2025, covering methods related to eliciting an immune response targeting anti-Müllerian hormone receptor, type II (AMHR2) [1]. - The patent includes methods for administering an immunogenic composition that encodes the AMHR2 polypeptide, specifically targeting the extracellular domain of human AMHR2 [3]. - Anixa holds exclusive worldwide rights to the patent, which was issued to Cleveland Clinic [3]. Group 2: Collaboration and Development - The ovarian cancer vaccine is being developed in collaboration with Cleveland Clinic and the National Cancer Institute, focusing on high-risk populations such as those with BRCA mutations [2]. - Anixa's therapeutic portfolio includes an ovarian cancer immunotherapy program utilizing chimeric endocrine receptor-T cell (CER-T) technology, which is distinct from traditional CAR-T therapies [4]. - The company is also developing additional cancer vaccines in collaboration with Cleveland Clinic to address various cancers, including breast, lung, colon, and prostate cancers [4].

Anixa Biosciences (ANIX) Update Summary Company Overview - Anixa Biosciences was reinvented in 2017 as a biotechnology company focusing on cancer therapies, with a robust pipeline of products currently in clinical trials [5][6] - The company has established partnerships with leading organizations such as the Cleveland Clinic and Moffitt Cancer Center, and receives funding from the U.S. Department of Defense and the National Cancer Institute [6][7] Financial Position - Anixa maintains a strong balance sheet with over two years of cash on hand, allowing for significant clinical milestones without frequent capital raises [8][12] - The company has a clean capital structure with 32 million shares of common stock and no warrants or preferred stock [10][11] Clinical Programs CAR T Therapy for Ovarian Cancer - The CAR T therapy targets terminally ill ovarian cancer patients and is currently in clinical trials at Moffitt Cancer Center [17][19] - The therapy utilizes a unique target, the follicle stimulating hormone receptor (FSHR), which is only found on ovarian cells and tumor blood vessels, allowing for a dual mechanism of action [29][31] - Early results show promising outcomes, with some patients living significantly longer than expected [39][41] - The FDA has approved the possibility of administering a second dose to patients showing initial responses, which is a rare approval for CAR T therapies [41][80] Breast Cancer Vaccine - The breast cancer vaccine aims to treat and prevent breast cancer, particularly targeting triple-negative breast cancer [42][43] - The vaccine is based on the alpha lactalbumin protein, which is produced during lactation and is found in many breast cancer cells [43][44] - Initial Phase I trials have shown strong immune responses and safety, with plans for a Phase II trial to compare the vaccine's effectiveness against standard care [51][55] - The vaccine has the potential to change the paradigm of cancer prevention, aiming for primary prevention in women without a history of cancer [59][60] Market Opportunities - Anixa is addressing large markets, including breast and ovarian cancer, with plans to expand into lung, prostate, and colon cancer [7][20][61] - The company anticipates significant market opportunities if their therapies prove successful, particularly in the context of the breast cancer vaccine [58][61] Strategic Partnerships and Funding - Discussions with potential pharmaceutical partners for both the CAR T therapy and breast cancer vaccine are ongoing, with hopes for fruitful collaborations in the near future [68] - The U.S. Department of Defense has funded the breast cancer vaccine study, recognizing its potential to change cancer treatment landscapes [70][71] Key Milestones and Future Outlook - Upcoming milestones include comprehensive clinical data presentations at the San Antonio Breast Cancer Conference and ongoing updates on patient outcomes for the CAR T therapy [64][66] - The company is optimistic about the potential for partnerships and funding based on the promising early results from their clinical trials [68][86]